
|Videos|December 23, 2020
Moving Forward in the Management of Acute GvHD
Author(s)Targeted Oncology
Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Breast Cancer News Roundup: June 2026
2
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
3
Q2 2026 in Oncology: A Look Back at FDA Approvals and Decisions
4
Ziftomenib Expands Role in Relapsed/Refractory NPM1-Mutated AML
5











































